Telomir Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Telomir Pharmaceuticals, Inc. (TELO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 150.00 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 150.00K shares.
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 37.50K shares.
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 0.00 shares.
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-12-31 was 0.00 shares.
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 2.09M shares, a 11.93% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 2.37M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 150.00K shares 10-Q · filed 2026-08-13 | ||||
| 2026-05-16 | 150.00K shares 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | 37.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 37.50K shares derived: sum of 2 quarters · filed 2026-03-17 | 2.09M shares 10-K · filed 2026-03-17 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 2.05M shares 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 2.05M shares 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | 2.37M shares 10-K · filed 2025-02-04 | |||
| 2024-09-30 | 2.37M shares 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |